Benign Bone Conditions That May Be FDG-avid and Mimic Malignancy

Semin Nucl Med. 2017 Jul;47(4):322-351. doi: 10.1053/j.semnuclmed.2017.02.004. Epub 2017 Apr 12.

Abstract

Positron emission tomography with the radiotracer 18F-fluoro-2-deoxy-d-glucose (FDG) plays an important role in the evaluation of bone pathology. However, FDG is not a cancer-specific agent, and knowledge of the differential diagnosis of benign FDG-avid bone alterations that may resemble malignancy is important for correct patient management, including the avoidance of unnecessary additional invasive tests such as bone biopsy. This review summarizes and illustrates the spectrum of benign bone conditions that may be FDG-avid and mimic malignancy, including osteomyelitis, bone lesions due to benign systemic diseases (Brown tumor, Erdheim-Chester disease, Gaucher disease, gout and other types of arthritis, Langerhans cell histiocytosis, and sarcoidosis), benign primary bone lesions (bone cysts, chondroblastoma, chondromyxoid fibroma, desmoplastic fibroma, enchondroma, giant cell tumor and granuloma, hemangioma, nonossifying fibroma, and osteoid osteoma and osteoblastoma), and a group of miscellaneous benign bone conditions (post bone marrow biopsy or harvest status, bone marrow hyperplasia, fibrous dysplasia, fractures, osteonecrosis, Paget disease of bone, particle disease, and Schmorl nodes). Several ancillary clinical and imaging findings may be helpful in discriminating benign from malignant FDG-avid bone lesions. However, this distinction is sometimes difficult or even impossible, and tissue acquisition will be required to establish the final diagnosis.

Publication types

  • Review

MeSH terms

  • Bone Diseases / diagnostic imaging*
  • Bone Neoplasms / diagnostic imaging*
  • Diagnosis, Differential
  • Fluorodeoxyglucose F18
  • Humans
  • Neoplasms
  • Positron-Emission Tomography*
  • Tomography, X-Ray Computed*

Substances

  • Fluorodeoxyglucose F18